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Abstract
Commercially available two component human fibrin sealants are commonly used to manufacture human fibrin-based biomaterials. How-
ever, this method is costly and allows little room for further tuning of the biomaterial. Human fibrinogen solutions offer a more cost-effective
and versatile alternative to manufacture human fibrin-based biomaterials. Yet, human fibrinogen is highly unstable and contains certain impu-
rities like human albumin. Within the context of biomaterials and tissue engineering we offer a simple yet novel solution based on classical
biochemical techniques to significantly reduce albumin in human fibrinogen solutions. This method can be used for various tissue engineer-
ing and biomedical applications as an initial step in the manufacturing of human fibrin-based biomaterials to optimise their regenerative
application.
© 2015 The Authors. Published by Elsevier B.V. on behalf of Société Française de Biochimie et Biologie Moléculaire (SFBBM).
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fibrin, an insoluble polymeric protein, is produced in re-
sponse to bleeding during the last step of the blood coagulation
cascade and is arranged in long fibrous chains [1]. The precursor
of fibrin is fibrinogen, a soluble protein produced in the liver and
found in blood plasma [2]. Tissue damage results in the cleavage
of fibrinogen by thrombin and its assembly to form fibrin. Fib-
rin is known to play a pivotal role in wound healing, making it
an ideal biomaterial choice for tissue engineering applications,
aiming at restoring tissue structure and function [3,4].
Due to its poor mechanical properties and high biodegradabil-
ity, fibrin, naturally a gel biomaterial, is often used in combina-
tion with other materials and/or chemically modified, i.e. cross-∗ Corresponding author. RAFT Institute of Plastic Surgery, Leopold Muller
Building, Mount Vernon Hospital, Northwood HA6 2RN, United Kingdom.
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access article under the CC BY-NC-ND license (http://creativecommons.org/licensinking, to tune and control its physical properties. Thus, fibrin-
ased biomaterials are biocompatible, biodegradable, have high
ffinity towards biological surfaces, enhance cell attachment,
issue repair and support angiogenesis [1,4]. They also serve
s suitable templates for controlled release of growth factors
5–7]. In addition, they have been used for stem cell delivery
nto the injury site, thus acting as cell carriers [8]. Due to its
ersatile nature, fibrin-based biomaterials have been tested as
otential scaffolds to regenerate bone, cardiac tissue, cartilage,
iver, nervous tissue, ocular tissue, skin, adipose tissue, tendons,
nd ligaments [9].
Fibrin requires the use of fibrinogen and thrombin as the
starting materials for its preparation [10]. Commonly, commer-
cially available two component human fibrin sealants are used
to manufacture human fibrin-based biomaterials. However, this
method is costly and allows little room for further modifica-
tions. Human fibrinogen solutions offer a more cost-effective
and versatile alternative to manufacture human fibrin-basedFrançaise de Biochimie et Biologie Moléculaire (SFBBM). This is an open
es/by-nc-nd/4.0/).
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Fig. 1. Graphical summary of the method proposed in this paper for removal of albumin from human fibrinogen preparations for manufacturing human
fibrin-based biomaterials.
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7iomaterials. Yet, human fibrinogen is highly unstable and con-
ains certain impurities like human albumin and salts (i.e. L-
rginine hydrochloride, sodium chloride, sodium citrate) to pre-
ent its degradation [11,12]. Albumin is the most abundant pro-
ein in plasma and is structurally very stable due to the presence
f 17 disulphide bonds. This allows albumin to remain stable
nder different conditions. However, its hydrophobic domains
ncrease the hydrophobicity of the fibrin biomaterial (cells find
t difficult to attach to hydrophobic surfaces) thereby reducing
he applications for the biomaterial [13,14]. Most importantly
lbumin is also known to have an anti-coagulation effect on
brinogen [14,15]. Due to the above mentioned reasons, albu-
in can have an inhibitory effect on fibrin activity during tissue
egeneration and therefore its levels should be reduced from hu-
an fibrinogen solutions. Dialysis is commonly used to remove
he salts present in protein solutions but albumin usually remains
concern due to its larger molecular weight. Hence, there is a
eed for a cost-effective and efficient method for removal of
lbumin from human fibrinogen solutions.
The aim of this work was to remove or significantly reduce the
oncentration of albumin present in human fibrinogen solutions
sing simple, classical biochemical techniques as an initial step
n the manufacturing of human fibrin-based biomaterials. For
his purpose, human fibrinogen was dialysed in dialysis tubing
ith a large molecular weight cut-off (100 kDa), which allowed
lbumin and other salts to pass through, leaving the fibrinogen in
he tube. Protein samples (pre and post dialysis) were analysed
sing SDS-PAGE electrophoresis by differentiating between the
olecular weight of the two proteins: human albumin has a
olecular weight of approximately 67 kDa while human fibrino-
en has an approximate molecular weight of 340 kDa. Finally, a
imple and rapid coagulation kinetic assay was performed on theialysed human fibrinogen to assess its functionality. Fig. 1 sum-
arises the different steps of the method described in this paper.
he ultimate goal of this work is to establish a simple, cost-
ffective and robust method for removing albumin from human
brinogen solutions that can be universally used as a previous
tep in the manufacturing of human fibrin-based biomaterials
ntended for tissue repair.
. Materials and methods
.1. Human fibrinogen solutions
Human fibrinogen from Bio Products Laboratory Ltd. (BPL,
K) was used as a control as it has a purity of approximately
00% and fibrinogen from CSL Behring Ltd. (RiaSTAP®, CSL
ehring Ltd., UK), with an approximate purity of 65–75 %, was
sed as the test product. The powders (1 g of fibrinogen + X g
f albumin + Y g of salts) were reconstituted as per manufac-
urers’ instructions, in sterile deionised water (50 ml). Samples
rom the diluted CSL protein solution (20 mg/ml of fibrino-
en + unknown concentration of albumin) were collected and
sed as pre-dialysis samples.
.2. Dialysis
The fibrinogen solutions were transferred into separate
00 kDa cut-off visking tubing (Spectra/Por® dialysis mem-
rane, flat nominal width = 16 mm, diameter = 10 mm, Spec-
rum Laboratories Inc., US), sealed using dialysis clips and
ialysed against 2-ethanesulfonic acid (MES)/NaCl buffer pH
.4 (150 mM NaCl + 25 mM MES), with three changes over
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Fig. 2. Top left, SDS-PAGE gel. Top right, BSA standard curve obtained from the SDS-PAGE gel by image analysis. Bottom right, table showing amount
(μg) and percentage of albumin in CSL product before and after the dialysis. Bottom left, coagulation kinetic assay showing functionality of dialysed human
fibrinogen.
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tapproximately 16 h, at 4 °C with gentle stirring in a 2 L cylin-
der. Post-dialysis solution was recovered using a pastette, the
volume measured, and the solution diluted to give a theoretical
20 mg/ml fibrinogen concentration assuming that no fibrinogen
was lost from the dialysis tube. This assumption was based on
both the cut-off size of the tube (100 kDa) and the size of fib-
rinogen (340 kDa): human fibrinogen is 3.4 times larger than the
pores of the dialysis membrane.
2.3. SDS-PAGE
To quantify the amount of albumin in CSL before and af-
ter dialysis, a non-reducing gel (8%) was run with a standard
curve of bovine serum albumin (BSA) (Sigma, UK) (2.5–20μg),
25 μg of fibrinogen pre-dialysis (CSL), 12.5 μg of fibrinogen
pre-dialysis (CSL), 25 μg of fibrinogen post-dialysis (CSL)
and 25 μg of control fibrinogen (BPL). 10 μl of each stan-
dard/sample was mixed with 3.3 μl of 3x non boil urea loading
dye. The gel was run at 100 V until the molecular weight markers
were separated and the bromophenol blue dye band reached the
bottom of the gel. The gel was removed from the electrophore-
sis rig and transferred to Instant-blue stain (Novexin Ltd, UK).
Bands were visualised after 15 min but left to increase in in-
tensity for 1 h. The gel was photographed in an EpichemiTM II
Darkroom (UVP Inc, US) and Optical density (OD) of bands
was analysed using LabWorksTM image acquisition and analy-
sis software (UVP Inc, US). Results were plotted into an OD
versus BSA concentration graph to obtain a standard curve for
BSA. The amount of albumin in CSL product before and after
dialysis was calculated from the standard BSA curve..4. Coagulation kinetic assay
In order to test the functionality of the dialysed fibrinogen
simple and rapid coagulation kinetic assay was carried out
fter the dialysis. Freshly prepared dialysed human fibrinogen
olution was diluted to 2% and 500 μl added into a 1 ml cuvette
FB55147, Fisher Scientific, UK), with 450 μl of MES/NaCl
H 7.4 buffer and 2 μl of 1M CaCl2. The coagulation assay was
tarted immediately upon thrombin addition (human thrombin
rom TISSEEL®, Baxter International Inc., US, 10 I.U./ml in
EPES/NaCl pH 7.4), with the solution being thoroughly mixed
y inversion using a fresh Parafilm M® cap before placing the
uvette in an M550 double beam UV/visible spectrophotometer
Camspec, UK). The Absorbance at 425 nm was recorded at
min intervals from time zero, until a plateau value was reached,
hich indicates complete coagulation.
. Results
Fig. 2 shows results from the SDS-PAGE gel, run with pre
nd post-dialysis CSL samples along with BSA standards and
PL fibrinogen sample. The main band seen in the middle of
he gel is albumin, which is approximately 67 kDa. On visually
nalysing the gel (Fig. 2), it was observed that the CSL product
fter dialysis had a reduced albumin band in comparison to the
re-dialysed albumin band. The amount of albumin before and
fter the dialysis step in CSL samples was calculated from the
SA standard curve.
Results showed that, when 25 μg of human fibrinogen pre-
ialysis were loaded onto the SDS-PAGE gel, it was calculated
hat the CSL product contained 7.95 μg of albumin. So, the
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Rotal amount of protein pre-dialysis loaded onto the gel was
5 + 7.95 = 32.95 μg. Therefore, in this case, the percentage
f albumin pre-dialysis was (7.95/32.95)∗100 = 24.13%. When
2.5 μg of human fibrinogen pre-dialysis were loaded, it con-
ained 4.74 μg of albumin, with a total amount of protein pre-
ialysis loaded onto the gel of 12.5 + 4.74 = 17.24μg and a per-
entage of albumin pre-dialysis of (4.74/17.24)∗100 = 27.49%.
herefore, the average percentage of albumin in the CSL product
re-dialysis was (24.13 + 27.49)/2 = 25.81%.
Post-dialysis, 25 μg of human fibrinogen were loaded onto
he SDS-PAGE gel (Fig. 2). It was calculated that it contained
.22 μg of albumin, making a total amount of protein post-
ialysis loaded onto the gel of 25 + 2.22 = 27.22 μg, with
percentage of albumin post-dialysis in the CSL product of
2.22/27.22)∗100 = 8.16%.
The total reduction of albumin compared to 25 μg pre-
ialysis was calculated as 7.95 μg - 2.22 μg = 5.73 μg.
herefore, the percentage of reduction of albumin was
5.73/7.95)∗100 = 72.08%. Compared to 12.5 μg pre-dialysis:
4.74∗2)μg – 2.22μg = 7.26μg. Thus, the percentage of reduc-
ion of albumin in this case was 7.26/(4.74∗2)∗100 = 76.58%.
herefore, the average percentage of reduction of albumin was
72.08 + 76.58)/2 = 74.33%.
The coagulation kinetic assay of the dialysed protein assesses
ts functionality. As it can be seen from Fig. 2, the mix starts co-
gulating moments after addition of thrombin. The coagulation
f the mix can be followed by measuring the Absorbance at
25 nm over time until after 20 min a plateau is reached in-
icating complete coagulation of the mix. This is a classical
oagulation curve [16] showing that the human fibrinogen after
ur proposed dialysis method is functional.
. Discussion
Fibrin, which is naturally a gel material, is an excellent bio-
aterial choice for tissue engineering as it is biocompatible,
nhances cell attachment and migration, promotes angiogene-
is and plays a pivotal role in important physiological processes
uch as wound healing [3,4,17]. However, depending on the
pecific application its mechanical and biodegradable properties
ay not be satisfactory and therefore it is often used in combina-
ion with other materials and/or chemically modified to enhance
ts physical properties [8,17–19]. The ideal fibrin biomaterial
or tissue engineering applications would exhibit adequate me-
hanical support to resist in vivo forces [17,18]. The appropriate
echanical properties are specific to each tissue application. For
xample, an elastic modulus of 6.67 MPa has been reported for
ack skin [20] while an elastic modulus of 18.6 GPa was mea-
ured by micro-tensile testing for cortical bone [21]. Reported
lastic modulus of fibrin gels are 0.93–6.49 kPa, depending on
brin concentration [22].
Commercially available two component fibrin sealants are
ommonly used as the starting product to manufacture human
brin-based biomaterials [1]. However, this option is expensive
nd allows little further modification of the biomaterial. Human
brinogen solutions are a more cost-effective option as starting
aterial as well as versatile in terms of further tuning of theiomaterial. Before they can be used, the impurities (salts and
lbumin) that accompany these products in order to stabilize fib-
inogen [11,12] must be removed to optimise the tissue regener-
tion process. Salts are easily removed by dialysis but albumin,
ith its larger molecular weight, remains a concern. The aim
f this work was to remove or significantly reduce the concen-
ration of albumin present in human fibrinogen solutions using
imple, classical biochemical techniques to establish a simple,
ost-effective and robust method that can be universally used
s a previous step in the manufacturing of human fibrin-based
iomaterials intended for tissue repair.
Results showed that the introduction of a 100 kDa cut-off dial-
sis step considerably and effectively removed albumin from hu-
an fibrinogen solution with further room for optimisation de-
ending on the manufacturing requirements. The advantages of
he proposed method are: 1) dialysis, SDS-PAGE electrophore-
is and UV/visible spectrophotometry are simple biochemical
echniques that use common, easy-to-use equipment normally
ound in the laboratory; 2) efficacy and 3) cost-effectiveness. The
resent method is routinely used in our laboratory to separate al-
umin from human fibrinogen solutions prior to manufacturing
brin-based biomaterials [23]. We consistently obtain a reduc-
ion of approximately 75% in the total albumin concentration
f human fibrinogen preparations, thus showing its robustness.
urther, optimising the 100 kDa cut-off dialysis step by either
dding more changes or dialysing for a longer period of time
ould aid in depletion of higher percentage of albumin, depend-
ng on its need and application. We believe this method could
e universally used as an initial step in manufacturing human
brin-based biomaterials intended for tissue repair after acute
rauma.
. Conclusions
Within the context of biomaterials and tissue engineering we
ffer a simple yet novel solution based on classical biochemical
echniques to significantly reduce albumin in human fibrinogen
olutions. This method can be used for various tissue engineer-
ng and biomedical applications as an initial step in the manu-
acturing of human fibrin-based biomaterials to optimise their
egenerative application.
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